Comparison of Neutralizing and Hemagglutination-Inhibiting Antibody Responses to Influenza A Virus Vaccination of Human Immunodeficiency Virus-Infected Individuals

Benne, C. A.; Kroon, F.P.; Harmsen, M.; Tavares, Luís; Kraaijeveld, C. A.; Jong, J.C. de

doi:10.1128/cdli.5.1.114-117.1998

Cited by 30 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statistical data were generated using GraphPad Prism 5 software. HI titers were transformed into logarithmic values and statistical significance between groups was analyzed by one-way analysis of variance (ANOVA) with Newman-Keuls post-test [25].…”

Section: Discussionmentioning

confidence: 99%

Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells

et al. 2020

View full text Add to dashboard Cite

Background: Influenza vaccine manufacturers traditionally use egg-derived candidate vaccine viruses (CVVs) to produce high-yield influenza viruses for seasonal or pandemic vaccines; however, these egg-derived CVVs need an adaptation process for the virus to grow in mammalian cells. The low yields of cell-based manufacturing systems using egg-derived CVVs remain an unsolved issue. This study aimed to develop high-growth cell-derived CVVs for MDCK cell-based vaccine manufacturing platforms. Methods: Four H7N9 CVVs were generated in characterized Vero and adherent MDCK (aMDCK) cells. Furthermore, reassortant viruses were amplified in adherent MDCK (aMDCK) cells with certification, and their growth characteristics were detected in aMDCK cells and new suspension MDCK (sMDCK) cells. Finally, the plaque-forming ability, biosafety, and immunogenicity of H7N9 reassortant viruses were evaluated.Results: The HA titers of these CVVs produced in proprietary suspension MDCK (sMDCK) cells and chicken embryos were 2-to 8-fold higher than those in aMDCK cells. All H7N9 CVVs showed attenuated characteristics by trypsindependent plaque assay and chicken embryo lethality test. The alum-adjuvanted NHRI-RG5 (derived from the fifth wave H7N9 virus A/Guangdong/SP440/2017) vaccine had the highest immunogenicity and cross-reactivity among the four H7N9 CVVs. Finally, we found that AddaVax adjuvant improved the cross-reactivity of low pathogenic H7N9 virus against highly pathogenic H7N9 viruses. Conclusions:Our study indicates that cell-derived H7N9 CVVs possessed high growth rate in new sMDCK cells and low pathogenicity in chicken embryo, and that CVVs generated by this platform are also suitable for both cell-and egg-based prepandemic vaccine production.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Statistical data were generated using GraphPad Prism (version 5.03) software (GraphPad Software). Statistical significance between groups was determined by transforming HI titers into logarithmic values and performing one-way analysis of variance (ANOVA) with the Newman-Keuls posttest, as described previously (56). Normalized HI titers were compared by Dunn-corrected Kruskal-Wallis tests.…”

Section: Methodsmentioning

confidence: 99%

Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice

Broecker

Liu

Sun

et al. 2018

J Virol

View full text Add to dashboard Cite

The hemagglutinin protein of H3N2 influenza viruses is the major target of neutralizing antibodies induced by infection and vaccination. However, the virus frequently escapes antibody-mediated neutralization due to mutations in the globular head domain. Five topologically distinct antigenic sites in the head domain of H3 hemagglutinin, A to E, have been previously described by mapping the binding sites of monoclonal antibodies, yet little is known about the contribution of each site to the immunogenicity of modern H3 hemagglutinins, as measured by hemagglutination inhibition activity, which is known to correlate with protection. To investigate the hierarchy of antibody immunodominance, five Δ1 recombinant influenza viruses expressing hemagglutinin of the A/Hong Kong/4801/2014 (H3N2) strain with mutations in single antigenic sites were generated. Next, the Δ1 viruses were used to determine the hierarchy of immunodominance by measuring the hemagglutination inhibition reactivity of mouse antisera and plasma from 18 human subjects before and after seasonal influenza vaccination in 2017-2018. In both mice and humans, mutations in antigenic site B caused the most significant decrease in hemagglutination inhibition titers compared to wild-type hemagglutinin. This study revealed that antigenic site B is immunodominant in the H3N2 influenza virus strain included in the current vaccine preparations. Influenza viruses rapidly evade humoral immunity through antigenic drift, making current vaccines poorly effective and antibody-mediated protection short-lived. The majority of neutralizing antibodies target five antigenic sites in the head domain of the hemagglutinin protein that are also the most sequence-variable regions. A better understanding of the contribution of each antigenic site to the overall antibody response to hemagglutinin may help in the design of improved influenza virus vaccines.

show abstract

“…This assay therefore measures the functional capability of antibodies at a specific dilution, rather than just the total quantity. In settings of impaired host immunity, such as HIV infection, the VMN titer is more sensitive than the HI titer ( 12 ); VMN is also better for detecting antibodies to avian influenza viruses ( 13 ). Multiple studies have demonstrated good correlation between HI titers and VMN titers in pregnant women following monovalent H1N1 vaccination ( 14 , 15 ), and now seasonal influenza vaccination ( 16 ).…”

Section: Assessment Of Immunogenicitymentioning

confidence: 99%

Immunogenicity and Clinical Efficacy of Influenza Vaccination in Pregnancy

Kay

Blish

2015

Front. Immunol.

View full text Add to dashboard Cite

Pregnant women are at high risk from influenza due to disproportionate morbidity, mortality, and adverse pregnancy outcomes following infection. As such, they are classified as a high-priority group for vaccination. However, changes in the maternal immune system required to accommodate the allogeneic fetus may alter the immunogenicity of influenza vaccines. A large number of studies have evaluated the safety of the influenza vaccine. Here, we will review available studies on the immunogenicity and efficacy of the influenza vaccine during pregnancy, focusing on both humoral and cellular immunity.

show abstract

Comparison of Neutralizing and Hemagglutination-Inhibiting Antibody Responses to Influenza A Virus Vaccination of Human Immunodeficiency Virus-Infected Individuals

Cited by 30 publications

References 23 publications

Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells

Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells

Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice

Immunogenicity and Clinical Efficacy of Influenza Vaccination in Pregnancy

Contact Info

Product

Resources

About